Literature DB >> 16690927

A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.

Viviana Buffa1, Donatella R M Negri, Pasqualina Leone, Roberta Bona, Martina Borghi, Ilaria Bacigalupo, Davide Carlei, Cecilia Sgadari, Barbara Ensoli, Andrea Cara.   

Abstract

Genetic immunization using viral vectors provides an effective means to elicit antigen-specific cellular immune responses. Several viral vectors have proven efficacious in inducing immune responses after direct injection in vivo. Among them, recombinant, self-inactivating lentiviral vectors are very attractive delivery systems, as they are able to efficiently transduce into and express foreign genes in a wide variety of mammalian cells. A self-inactivating lentiviral vector was evaluated for the delivery of human immunodeficiency virus 1 (HIV-1) envelope sequences in mice in order to elicit specific immune responses. With this aim, BALB/c mice were immunized with a single injection of self-inactivating lentiviral vectors carrying either the full-length HIV-1(HXB2) Rev/Env (TY2-IIIBEnv) or the codon-optimized HIV-1(JR-FL) gp120 (TY2-JREnv) coding sequence. Both vectors were able to elicit specific cellular responses efficiently, as measured by gamma interferon ELISPOT and chromium-release assays, upon in vitro stimulation of splenocytes from BALB/c immunized mice. However, only the TY2-JREnv-immunized mice were able to elicit specific humoral responses, measured as anti-gp120 antibody production. These data provide the first evidence that a single, direct, in vivo administration of a lentiviral vector encoding a viral gene might represent a useful strategy for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690927     DOI: 10.1099/vir.0.81706-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 2.  Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Authors:  Yukai He; David Munn; Louis D Falo
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

3.  Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.

Authors:  Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

4.  Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice.

Authors:  Donatella R M Negri; Zuleika Michelini; Silvia Baroncelli; Massimo Spada; Silvia Vendetti; Roberta Bona; Pasqualina Leone; Mary E Klotman; Andrea Cara
Journal:  J Biomed Biotechnol       Date:  2010-05-19

5.  Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.

Authors:  Anne-Sophie Beignon; Karine Mollier; Christelle Liard; Frédéric Coutant; Sandie Munier; Julie Rivière; Philippe Souque; Pierre Charneau
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

6.  Development and use of SIV-based Integrase defective lentiviral vector for immunization.

Authors:  Zuleika Michelini; Donatella R M Negri; Silvia Baroncelli; Massimo Spada; Pasqualina Leone; Roberta Bona; Mary E Klotman; Andrea Cara
Journal:  Vaccine       Date:  2009-06-11       Impact factor: 3.641

Review 7.  Vaccines: from empirical development to rational design.

Authors:  Christine Rueckert; Carlos A Guzmán
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

Review 8.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

Review 9.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

10.  Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine.

Authors:  Frédéric Coutant; Marie-Pascale Frenkiel; Philippe Despres; Pierre Charneau
Journal:  PLoS One       Date:  2008-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.